HLA-DR anticorps

N° du produit ABIN4949753

Cet anticorps anti-HLA-DR Monoclonal Souris (Clone IPO-10) (ABIN4949753) détecte spécifiquement HLA-DR dans FACS et IF. L’anticorps est réactif avec des échantillons de Humain et Singe.

Aperçu rapide pour HLA-DR anticorps (ABIN4949753)

Antigène: HLA-DR

Reactivité: Humain, Singe

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp HLA-DR est non-conjugé

Application: Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: IPO-10

Détail du produit anti-HLA-DR anticorps

Purification: Protein G affinity chromatography

Immunogène: Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the HLA-DR antibody.

Isotype: IgG3 kappa

Information d'application

Indications d'application: Optimal dilution of the HLA-DR antibody should be determined by the researcher.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL

Restrictions: For Research Use only

Stockage

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the HLA-DR antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Détails sur HLA-DR

Antigène: HLA-DR

Autre désignation: HLA-DR (MHC II)

Sujet: MAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and than reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50 % of cells). The mAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This mAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70 % of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

Pathways: Human Leukocyte Antigen (HLA) in Adaptive Immune Response